New findings from the VESTIGE trial reveal the effectiveness of Dupixent (dupilumab) in managing uncontrolled moderate-to-severe asthma. Presented at the 2024 AAAAI Annual Meeting, the trial employed functional respiratory imaging (FRI) to assess Dupixent’s impact on lung function.
Sanofi and Regeneron presented the late breaking results of the VESTIGE trial, showed significant reductions in airway inflammation and improvements in mucus plug scores and lung function among patients receiving Dupixent compared to those on placebo. This suggests Dupixent’s potential in alleviating respiratory symptoms and enhancing quality of life for asthma patients.
While the safety profile of Dupixent was consistent with previous findings, common adverse events included cardiac disorders, infections, and injection site reactions. Overall, these findings highlight Dupixent as a promising treatment option for severe asthma.